Biomarin Pharmaceutical Inc. Earnings

Biomarin Pharmaceutical Inc.’s revenue jumped 4.08% since last year same period to $776.13Mn in the Q3 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated -5.97% fall in its revenue since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit fell -128.98% since last year same period to $-30.74Mn in the Q3 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated -112.78% fall in its net profits since last 3-months.

Biomarin Pharmaceutical Inc.’s net profit margin fell -127.85% since last year same period to -3.96% in the Q3 2025. On a quarterly growth basis, Biomarin Pharmaceutical Inc. has generated -113.59% fall in its net profit margins since last 3-months.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.82 - a -0.81% fall from last quarter’s estimates.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at 0.82.

Biomarin Pharmaceutical Inc.’s earning per share (EPS) jumped 157.14% since last year same period to 1.44 in the Q2 2025. This indicates that the Biomarin Pharmaceutical Inc. has generated 157.14% annual rate of jump in its earning per share (EPS) in the last 4 quarters.